Pages

.

Showing posts with label Laboratories. Show all posts
Showing posts with label Laboratories. Show all posts

Millennium Laboratories Expands Pharmacogenetic Test to Help Clinicians Prescribe the Right Medicine at the Right Dose

Millennium PGT. (PRNewsFoto/Millennium Laboratories, LLC)Millennium Laboratories. (PRNewsFoto/Millennium Laboratories, LLC)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";SAN DIEGO, July 17, 2014 /PRNewswire/ -- Millennium Laboratories announced today that it has expanded its pharmacogenetic test (Millennium PGTSM) to include seven additional genes. The expanded test gives clinicians additional, objective information, based on patients' own genetics to help determine their potential response to a broad list of medications commonly prescribed across four key therapeutic areas, including pain, mental health, addiction and cardiovascular therapy.

Millennium PGT now analyzes clinically relevant genetic variants for 11 genes related to medication response to help clinicians individualize prescribing decisions. The Millennium Analysis of Patient Phenotype (MAPP®) Report provides clinicians with evidence based and clinically actionable information to support medication decisions for over 30 commonly prescribed medications across 14 medication classes. The MAPP Report also includes information for 20 medications with pharmacogenetic information or specific recommendations related to use in their U.S. Food and Drug Administration approved labels.  

"Millennium is providing clinical tools for improving care for all patients, and through investments in the newest technologies, we have delivered on that promise with our expanded PGT offering," said Chief Executive Officer, Brock Hardaway. "This milestone allows us to continue fulfilling a crucial need in health care, and offers additional tools that may help providers make more effective, individualized medication choices to get their patients on the path to wellness faster."

This saliva-based test helps clinicians determine, based on genetics, which medications are more likely to work for an individual patient, while helping them to avoid prescribing those more likely to cause adverse reactions. Millennium PGT helps health care providers minimize trial and error prescribing potentially shortening the time it takes for patients to feel better.

"It is very good to know it's the right drug, and it's very good to know that you're giving the right dose, and it's good to know that that patient is going to respond in the way you hope," said Dr. Manya Helman, family practice physician, Salem, Ore. "To be able to give the right drug, in the right dose, to right patient is exactly what our goal is."

In addition to the core offerings of CYP2D6, CYP2C19, CYP2B6, and UGT2B15, this expansion will significantly broaden Millennium's PGT menu to include CYP2C9, CYP3A4, CYP3A5, as well as VKORC1, COMT, MTHFR and OPRM1. Paired with PGT ConsultSM, a mobile application that provides evidence-based clinical decision support to health care providers, Millennium PGT is helping clinicians optimize patient care. 

About Millennium PGT
Millennium PGT is a laboratory developed pharmacogenetic test that analyzes clinically important genetic variations associated with how patients may respond to many commonly prescribed medicines. Millennium PGT is a saliva based test that provides clinicians with objective information that may help them individualize medication treatment decisions.

Millennium PGT is paired with the MAPP® Report, which provides clinicians with actionable information, based on a patient's own genetics, about their potential response to over 30 medications prescribed across four key therapeutic areas: pain, mental health, addiction and cardiovascular therapy. Together with PGT Consult, a mobile application that provides evidence-based clinical decision support, the combination of tools helps clinicians individualize medications to their patient's unique genetics, maximizing the opportunity for successful outcomes.

About Millennium Laboratories
Millennium Laboratories, a leader in the science of medication monitoring and pharmacogenetics, is transforming the way health care professionals monitor and manage their patients' medication therapy. Through the use of advanced technology, supported by research and education, Millennium helps practitioners personalize care for patients. Building on this strong foundation, Millennium aims to expand its impact by helping more people affected by chronic illnesses and dedicating itself to filling a crucial unmet need in health care. More information can be found at www.millenniumlabs.com.

Logo - http://photos.prnewswire.com/prnh/20140716/127829
Logo - http://photos.prnewswire.com/prnh/20120224/MM59482LOGO

SOURCE Millennium Laboratories, LLC

RELATED LINKS
http://www.becausepainmatters.com

reade more... Résuméabuiyad

Clontech Laboratories, Inc. Partners With Vectalys SAS to Provide Highly Concentrated Purified Lentiviral Particles

MOUNTAIN VIEW, Calif., May 5, 2014 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that it has partnered with Vectalys SAS to combine Clontech's Living Colors® fluorescent protein and Tet-On® 3G technologies with Vectalys' expertise in providing the highest quality ready-to-use lentiviral particles as vectors for gene delivery.

Carol Lou, General Manager of Clontech Laboratories, Inc., comments: "Clontech has a long history of leadership in the development of viral gene delivery tools, including numerous innovative Lenti-X™, Retro-X™ and Adeno-X™ products. We are pleased to collaborate with Vectalys to provide high quality, concentrated lentiviral particles which will make it easier to deliver Clontech's technologies at high copy numbers to virtually any cell type, including primary cells."

"We strongly believe that using highly concentrated and purified lentiviral tools is the key factor for successful cell transduction, especially for hard-to-transfect and delicate cells," says Pascale Bouille, Vectalys Chief Executive Officer. "The combination of Vectalys' process and Clontech's technologies provides our customers with a unique and optimal gene delivery offer."

The initial product offering will include somatic cell reprogramming kits used to generate induced pluripotent stem cells (iPS cells) as well as ready-to-use lentiviral particles for fluorescent labeling of whole cells and of specific subcellular structures. The somatic cell reprogramming kits leverage Clontech's Tet-On 3G technology to provide tight transcriptional control of genes involved in maintaining embryonic stem cell-like properties, in order to generate iPS cells.

About Clontech Laboratories, Inc.
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech® and Takara® brands. Key products include SMARTer® cDNA synthesis kits for a variety of samples and applications, including NGS; high-performance qPCR and PCR reagents (including the Ex Taq™, LA Taq™, Titanium®, and Advantage® enzymes); RT enzymes and SMART™ library construction kits; the innovative In-Fusion® cloning system; Tet-based inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information, visit www.clontech.com.

About Takara Bio Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is used as a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.

About Vectalys SAS
Vectalys SAS (Toulouse, France) is a biotechnology company that develops, manufactures and markets gene transfer tools for the development of cellular and animal models for the validation of candidate genes and drug screening. The company provides its expertise in producing highly concentrated and purified viral vectors and the knowledge required for the development of predictive experimental cellular models and genetically modified animals. For more information visit www.vectalys.com

Info - http://photos.prnewswire.com/prnh/20140502/83852
Photo - http://photos.prnewswire.com/prnh/20140502/83854
Photo - http://photos.prnewswire.com/prnh/20140502/83851
Logo - http://photos.prnewswire.com/prnh/20131021/SF99259LOGO

SOURCE Clontech Laboratories, Inc.

RELATED LINKS
http://www.clontech.com

reade more... Résuméabuiyad

Nelson Laboratories to Offer Free Biocompatibility Consultations During BIOMEDevice San Jose

Nelson Laboratories. (PRNewsFoto/Nelson Laboratories)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";SALT LAKE CITY, Nov. 19, 2013 /PRNewswire/ -- Nelson Laboratories (www.nelsonlabs.com) will offer free biocompatibility consultations in its booth (#321) during BIOMEDevice in San Jose, CA Dec. 4-5, 2013 with expert Thor Rollins, biocompatibility specialist. Those interested in a consultation should register at Marketing@NelsonLabs.com.

(Logo:  http://photos.prnewswire.com/prnh/20120727/LA47745LOGO)

Rollins will also present, "Selection, Testing and Validation of Medical Devices According to ISO 10993," from 10:00 am to 12:00 pm Dec. 5. The presentation is free, but participants should register at http://www.canontradeshows.com/expo/biomed13/conf_Nelson_form.html

"During the presentation, we will discuss materials that can have an impact on test results, which specific tests to use, and how to confirm test results," said Rollins. "For those who want to dig a little deeper, we will also be conducting free biocompatibility consultations."

During the consultations, participants can go over any biocompatibility topic they wish with Rollins. Some suggested topics may include:

Setting up a biocompatibility test plan What happens if you fail a biocompatibility test Materials characterization testing ISO updates/changes Materials justificationsRollins' presentation will cover:

ISO 10933 Test Requirements and how Materials Could Impact Biocompatibility Testing:

An overview of the most common biocompatibility tests and what materials could impact the results How FDA and other regulatory agencies will interpret your results or test selection How the new FA Draft Guidance might impact your future testing How to categorize you device according to ISO 10993Materials Characterization for Medical Devices per ISO 10993-17,18:

The correct way to extract your device to look for extractables and leachables What tests to run to identify and quantify the compounds How to determine the potential toxicological impact of the compoundsWhat To Do If You Fail A Compatibility Test:

How to confirm the result How to trouble shoot and ways to improve you device How to justify a failureAbout Nelson Laboratories

Nelson Laboratories is a leading provider of full, life-cycle microbiology testing services. We are known for exceptional quality, but we look beyond the testing process and partner with you to achieve your long-term business goals. It's what we call The Science of Success™. Learn how we can help move your products to market quickly and safely. Visit www.nelsonlabs.com.

Contact:
Cory Maloy
Snapp Conner PR
801-319-7900
cory@snappconner.com

SOURCE Nelson Laboratories

RELATED LINKS
https://www.nelsonlabs.com

reade more... Résuméabuiyad